Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nationwide implementation and evaluation of the Tumor-First workflow for genetic testing in ovarian carcinoma.

International journal of cancer - 1 Aug 2025

Witjes Vera M, de Hullu Joanne A, Hermkens Dorien M A, Smolders Yvonne H C M, Swillens Julie E M, Slob Sarah-Lotte, Bosse Tjalling, Mourits Marian J E, Ausems Margreet G E M, Ligtenberg Marjolijn J L, Hoogerbrugge Nicoline

Abstract excerpt

Despite international agreement on the importance of tumor DNA testing and germline testing for determining PARP inhibitor treatment eligibility in patients with ovarian carcinoma (OC) and for cancer prevention in their relatives, the optimal strategy remains under debate. In the Netherlands, the "Tumor-First workflow" was initiated and implemented nationwide: a well-validated tumor DNA test is the primary test...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fanconi Anemia Complementation Group N Protein

Share to Fanconi Anemia Complementation Group Proteins

Share to Netherlands

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to RNA Helicases

Share to Workflow

Source

Open in PubMed Open full text

Identifiers

PMID: 40240123
DOI: 10.1002/ijc.35440
PMCID: PMC12141975

Genes

BRCA1
BRIP1
PALB2
RAD51C

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nationwide implementation and evaluation of the Tumor-First workflow for genetic testing in ovarian carcinoma.PMID 40240123Read ↗

Opportunities to improve detection of genetic predisposition for ovarian cancer applying the Tumor-First workflow.Semantic proximity Read ↗

Optimizing the detection of hereditary predisposition in women with epithelial ovarian cancer: nationwide implementation of the Tumor-First workflow.Semantic proximity Read ↗

[Genetic testing in epithelial ovarian cancer: implementation of the 'Tumor-First' workflow].Semantic proximity Read ↗

Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic PredispositionSemantic proximity Read ↗

Evaluation of BRCA1/2 testing rates in epithelial ovarian cancer patients: lessons learned from real-world clinical data.Semantic proximity Read ↗

Clinical Integration of Germline Findings from a Tumor Testing Precision Medicine ProgramSemantic proximity Read ↗

Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH).Semantic proximity Read ↗

The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First?Semantic proximity Read ↗

<em>BRCA1/2</em> Testing Landscape in Ovarian Cancer: A Nationwide, Real-World Data StudySemantic proximity Read ↗

Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic.Semantic proximity Read ↗

Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.Semantic proximity Read ↗

Re-evaluating hereditary breast and ovarian cancer risk: clinical impact of updated multigene panel sequencing and genetic counseling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.